388 related articles for article (PubMed ID: 27913543)
81. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
82. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
[TBL] [Abstract][Full Text] [Related]
83. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
84. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
85. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):605-609. PubMed ID: 29222310
[TBL] [Abstract][Full Text] [Related]
86. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
Chang H; Sher GD; Blanchette VS; Teitel JM
Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
[TBL] [Abstract][Full Text] [Related]
87. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
[TBL] [Abstract][Full Text] [Related]
88. Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices.
Liu W; Xue F; Poon MC; Chen L; Jin Z; Zhang L; Yang R
Br J Haematol; 2021 Aug; 194(4):750-758. PubMed ID: 34340252
[TBL] [Abstract][Full Text] [Related]
89. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs.
Santagostino E; Morfini M; Auerswald GK; Benson GM; Salek SZ; Lambert T; Salaj P; Jimenez-Yuste V; Ljung RC
Haemophilia; 2009 Sep; 15(5):983-9. PubMed ID: 19712172
[TBL] [Abstract][Full Text] [Related]
90. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
[TBL] [Abstract][Full Text] [Related]
91. Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
[TBL] [Abstract][Full Text] [Related]
92. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
93. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
[TBL] [Abstract][Full Text] [Related]
94. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
95. Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies.
Baghaipour MR; Steen Carlsson K
Eur J Haematol; 2015 Feb; 94 Suppl 77():30-7. PubMed ID: 25560792
[TBL] [Abstract][Full Text] [Related]
96. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
[TBL] [Abstract][Full Text] [Related]
97. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Young G; Cooper DL; Gut RZ;
Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
[TBL] [Abstract][Full Text] [Related]
98. Inhibitor economics.
Teitel J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
[TBL] [Abstract][Full Text] [Related]
99. Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.
Mancuso ME; Chantarangkul V; Clerici M; Fasulo MR; Padovan L; Scalambrino E; Peyvandi F; Tripodi A; Santagostino E
Haemophilia; 2016 Jul; 22(4):e292-300. PubMed ID: 27197961
[TBL] [Abstract][Full Text] [Related]
100. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.
Konkle BA; Ebbesen LS; Erhardtsen E; Bianco RP; Lissitchkov T; Rusen L; Serban MA
J Thromb Haemost; 2007 Sep; 5(9):1904-13. PubMed ID: 17723130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
